Defining remission in psoriatic arthritis.
Driven in part by the introduction of highly effective agents, there has been growing interest in the overall therapeutic approach to patients with psoriatic arthritis (PsA). As with any form of arthritis, the goal of treatment for PsA would be to improve the outcome to the greatest extent possible. In other conditions, such as rheumatoid arthritis, recent discussions have centered on how best to define "remission." For patients with PsA, the heterogeneity among disease manifestations as well as the need to validate outcome measures make definition of remission challenging. In this paper we present a number of key principles and considerations critical to laying the groundwork for defining remission in PsA.
Kavanaugh
A
A
Center for Innovative Therapy, Division of Rheumatology, Allergy, and Immunology, University of California San Diego, La Jolla, CA 92093-0943, USA. akavanaugh@ucsd.edu
Fransen
J
J
D015535:Arthritis, Psoriatic / Q000150:complications / Q000188:drug therapy*; D023381:Endpoint Determination; D005384:Finger Joint / Q000276:immunology; D006801:Humans; D007249:Inflammation / Q000188:drug therapy; D017410:Practice Guidelines as Topic; D012016:Reference Values; D012074:Remission Induction; D012720:Severity of Illness Index; D014033:Toe Joint / Q000276:immunology